Browsing Tag
Lykos Therapeutics
2 posts
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.
Is the cure for PTSD waiting in the wings? FDA says not yet!
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has decided not to approve the…